Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

GBS Inc. GBS NASDAQ

NASDAQ Global Market • Healthcare • Medical - Devices • US • USD

SharesGrow Score
38/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

GBS Inc. (GBS) is a Medical - Devices company in the Healthcare sector, currently trading at $0.47. It has a SharesGrow Score of 37/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Financials: revenue is $3M, +111.1%/yr average growth. Net income is $11M (loss), growing at -9.2%/yr. Net profit margin is -346.2% (negative). Gross margin is 40.8% (-59.2 pp trend).

Balance sheet: total debt is $281,805 against $3M equity (Debt-to-Equity (D/E) ratio 0.09, conservative). Current ratio is 0.77 (tight liquidity). Debt-to-assets is 3.4%. Total assets: $8M.

Analyst outlook: 1 / 1 analysts rate GBS as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 28/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).

GBS SharesGrow Score Overview

46/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GBS

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
GBS: +111.1%/yr revenue is, -9.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet GBS: Debt-to-Equity (D/E) ratio 0.09 (conservative), Current ratio is 0.77 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
GBS: Gross margin is 40.8% (-59.2 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 1 / 1 analysts rate GBS as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
GBS: Net profit margin is -346.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.36-2.89
Volume9.03K
Avg Volume (30D)51.58K
Market Cap$433.58K
Beta (1Y)0.00
Share Statistics
EPS (TTM)-2.00
Shares Outstanding$5.27M
IPO Date2020-12-23
Employees12
CEOHarry Simeonidis
Financial Highlights & Ratios
Revenue (TTM)$3.05M
Gross Profit$1.25M
EBITDA$-11.85M
Net Income$-10.57M
Operating Income$-10.64M
Total Cash$1.02M
Total Debt$281.81K
Net Debt$-738.1K
Total Assets$8.25M
Price / Earnings (P/E)-0.2
Price / Sales (P/S)0.14
Analyst Forecast
Rating ConsensusBuy
Analysts Covering1
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS36151G1058

Price Chart

Track all markets on TradingView
GBS
GBS Inc. ↗  ·  NASDAQ Global Market
Healthcare • Medical - Devices
0.36 52WK RANGE 2.89

People Also View

LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
 RHHBF
RHHBF
Roche Holding AG
$415.00
-0.84%
 RHHBY
RHHBY
Roche Holding AG
$50.99
-0.08%
 AZN
AZN
AstraZeneca PLC
$201.21
-1.55%
 NVS
NVS
Novartis AG
$152.08
-0.85%
 MRK
MRK
Merck & Co., Inc.
$117.90
-1.72%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message